Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Guardant Health

Thumbnail
March 31, 2021

Illumina hits the antitrust wall – again

The quest for the Grail is beset with challenges.

Thumbnail
March 03, 2021

Agilent’s liquid biopsy Resolution

Article image
Vantage logo
January 20, 2021

Focus on Covid-19 does not distract the FDA

Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.

Article image
Vantage logo
October 27, 2020

Exact chases its dream with $1.7bn Thrive deal

Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.

Article image
Vantage logo
September 25, 2020

Exact gatecrashes the liquid biopsy party

Preliminary data on its pan-cancer blood test appear surprisingly competitive.

Article image
Vantage logo
September 16, 2020

With its liquid biopsy approval, Foundation Medicine takes on Guardant

The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.

Article image
Vantage logo
September 10, 2020

Grail seeks to float at last

Article image
Vantage logo
August 10, 2020

Guardant pips Roche to liquid biopsy approval

The liquid biopsy era is finally here.

Article image
Vantage logo
June 05, 2020

How best to develop a liquid biopsy?

Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.

Article image
Vantage logo
January 08, 2020

2019 was all about execution for smaller device makers

New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.

Article image
Vantage logo
November 27, 2019

Veracyte’s nasal lung cancer test results raise questions

Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.